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mentation of patients with NEN should include the most rel-
evant data characterizing an individual patient from the first 
contact with his/her physician/hospital until his/her last pre-
sentation during follow-up. It is advocated that follow-up oc-
curs in specialized NEN centers with regular NEN tumor 
boards with expert panels. The follow-up should be in accor-
dance with the ENETS consensus guidelines from 2011 and 
2016, the present and coming WHO classification and ENETS/
UICC recommendations for TNM staging. The recommenda-
tions for follow-up in patients with thymic, bronchopulmo-
nary and gastroenteropancreatic NEN are given in Table 1. 
However, it should be stressed that evidence-based studies 
for follow-up are largely missing.  © 2017 S. Karger AG, Basel 
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 Abstract 
 ENETS consensus recommendations for the standards of care 
in neuroendocrine neoplasms (NEN) concerning follow-up 
and documentation are considered in this review. The docu-
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 Introduction 
 The documentation of patients with neuroendocrine 
neoplasms (NEN) should include the most relevant data 
characterizing an individual patient from the first con-
tact with his/her physician/hospital until his/her last pre-
sentation during follow-up. The documentation should 
be both simple but nevertheless as complete as possible 
and should include basic demographic details to identify 
a specific patient, family history, tumor histology and bi-
ology, course of the disease, tumor board evaluations, di-
agnostic tests, and therapeutic interventions. Additional 
data about biological samples, such as tumor specimens 
preserved in paraffin-embedded or fresh frozen samples 
and the patient’s samples like blood or serum, would be 
of high interest for current and future translational re-
search. This information is essential for treatment and 
follow-up strategies adjusted to the specific features of 
the tumor of the patient. Furthermore, standardized doc-
umentation acts as a key precondition to learn more 
about patients with specific tumor subtypes and regard-
ing the impact of treatment modalities on the course of 
the disease. In the present clinical setting, the timing of 
data collection and content of documented data vary 
considerably. Therefore, comparison of data from differ-
ent centers is frequently hampered by lack of data uni-
formity.
 During the ENETS Standards of Care Conference Ad-
visory Board meeting organized in Antibes, France in 
2015, a group of physicians with extensive experience in 
the clinical care of patients with gastroenteropancreatic 
(GEP), bronchopulmonary (BP) and thymic NEN met to 
write recommendations on the unified collection of data 
and suggested time intervals for follow-up investigations. 
These guidelines recognize the diversity of tumor sub-
types, the actual WHO and TNM classifications, the in-
dividual clinical course of the disease as well as the re-
source implications relevant to the growing costs of the 
European health care systems. Particular attention was 
paid to recommend only those investigations that would 
have a significant impact on further therapeutic strate-
gies.
 It is advocated that follow-up occurs in specialized 
NEN centers or at least in hospitals with close collabora-
tion with specialized NEN centers. It is of minor impor-
tance which specialty (e.g., oncology, gastroenterology, 
endocrinology, pulmonology or surgery) follows the pa-
tient as long as experienced NEN specialists are present. 
Regularly NEN tumor boards with expert panels are es-
sential for follow-up. Besides all new patients, patients 
with recurrence or progression as well as patients with 
other relevant problems during follow-up should be pre-
sented at the multidisciplinary tumor board.
 Documentation at Follow-Up Should Adhere to 
the Present WHO Classification and Recognize the 
ENETS Consensus Guidelines and Recommendations 
for TNM Staging 
 The panel agreed that the following categories best de-
fine the different tumor entities observed in the clinical 
setting. The categories follow the WHO 2010 classifica-
tion  [1] as well as the ENETS consensus guidelines from 
2011  [2] and 2016  [3] and the recommendations for 
TNM staging  [4, 5] in order to better compare data from 
different centers. We are aware that a revised WHO clas-
sification will be published within the next few years, also 
considering G3 neuroendocrine carcinomas (NEC G3, 
poorly differentiated) versus G3 neuroendocrine tumors 
(NET G3, well differentiated) as different entities based 
upon differentiation. This may refine the current classi-
fications, if an objective definition of differentiation is 
achieved. This subclassification may have an impact on 
treatment, but may not change the general follow-up 
procedures and recommendations. It should be stressed 
that evidence-based studies for follow-up are largely 
missing.
 In this article, we have revised the previous recom-
mendations  [6] and introduced a new set-up, which we 
find easier to apply on the daily routine for follow-up on 
patients with GEP, BP and thymic NEN ( Table 1 ). For BP 
NEN, typical and atypical carcinoids as well as large-cell 
neuroendocrine carcinomas have been included as per 
ENETS guidelines  [7] and Danish guidelines  [8] . Small-
cell lung cancer is not included in the article as it is be-
yond the scope of these recommendations and as it is 
dealt with in several other guidelines. We have included 
a suggested follow-up regime for thymic NEN, although 
evidence for follow-up in these tumor types is lacking.
 Firstly, the different NEN are divided according to the 
organ of the primary tumor, including cancer of un-
known primary. Secondly, the tumors are recorded ac-
cording to their grading (GEP NEN), differentiation (thy-
mic and BP NEN), status, and operative outcome, respec-
tively ( Table 1 ). Data on stage (TNM – including size of 
the primary but also tumor burden), tumor aggressive-
ness (stable vs. progressive disease), functionality, chro-
mogranin A (CgA) levels, and hereditary disease, which 
all may have an impact and thus may affect the follow-up 
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 Table 1. Tumor-specific recommendations for follow-up (in most cases life-long)
Organ Status F-U Every CgA Markersa Endoscopy CT/MRI/USb SRIc FDG-PET Comments
Bronchopulmonary
Typical resected yes 6 – 12 m yes 5-HIAAd
relevant tumor 
hormonesd
bronchoscopym
5 – 10 y
6 – 12 m 12–
36 me
EBUS may be required if 
recurrence is suspected
Typical residual tumor 
or metastases
yes 3 – 6 m yes 5-HIAAd
relevant tumor 
hormonesd
bronchoscopym
5 – 10 y
3 – 6 m 12–
36 me
12–
24 ml
EBUS may be required if 
progression  is suspected
Atypical resected yes 3 – 6 m yes 5-HIAAd
relevant tumor 
hormonesd
bronchoscopym
1 – 3 y
(3)–6 m 12–
24 me,f
12–
24 ml
EBUS may be required if 
recurrence is suspected
Atypical residual tumor 
or metastases
yes 3 m yes 5-HIAAd
relevant tumor 
hormonesd
bronchoscopym
1 – 3 y
3 – 6 m 12–
24 me,f
12–
24 ml
EBUS may be required if 
progression  is suspected
LCNEC
poorly diff.
resected/
nonresected
yes 2 – 3 m yesd NSEd
relevant tumor 
hormonesd
bronchoscopym
if symptoms
2 – 3 m 12–
24 me,f
12–
24 ml
bronchoscopy indicated if 
rebiopsy, argon-beam or 
bronchial stent is required;
EBUS may be required if 
recurrence or progression is 
suspected
Thymic
Typical resected/
residual tumor 
or metastases
yes 6 – 12 m yes relevant tumor 
hormonesd
6 – 12 m 12–
36 me,f
12–
36 me,f
Atypical resected/
residual tumor 
or metastases
yes 3 – 6 m yes relevant tumor 
hormonesd
3 – 6 m 12–
24 me,f
6–
24 me,f
Poorly diff. resected/
nonresected
yes 2 – 3 m yesd relevant tumor 
hormonesd
3 – 6 m 12–
24 me,6
6–
24 me,f
Esophagus
G1–G2 NET resected/
nonresected
yes 3 m yesd none 12 m 
or symptoms
3 – 6 m 12–
24 me
EUS may be required if 
recurrence or progression is 
suspected
G3 NEC resected/
nonresected
yes 3 m yesd none 12 m, 
or symptoms
2 – 3 m 12–
24 me,6
6–
24 ml
EUS may be required if 
recurrence or progression is 
suspected
Stomach
Type 1 
G1–G2 NET
resected/
nonresected
yes 6 – 12 m yesg gastring
B12 vitamin
12 m, 
or symptoms
noh noh no EUS may be required if 
recurrence or progression is 
suspected
Type 2
G1–G2
resected/
nonresected
yes 6 – 12 m yes gastrin
Ca2+, PTH
6 – 12 m, 
or symptoms
12 m 12–
24 me,f
no EUS may be required if 
recurrence or progression is 
suspected
Type 3
G1–G3 NEC/NET
resected/
nonresected
yes 2 – 3 m yesd none 6 – 12 m, 
or symptoms
2 – 6 m 12–
24 me,f
12–
24 ml
EUS may be required if 
recurrence or progression is 
suspected
Duodenum
Gastrinoma
G1–G2
resected yes 6 – 12 m yes gastrin,
Ca2+, PTH
12 m, 
or symptoms
12 m 12–
24 me
Gastric pH measurement or 
secretin test may be 
performed if symptoms 
recur; EUS may be required
if recurrence is suspected
Gastrinoma
G1-G2
nonresected yes 3 – 6 m yes gastrin, 
Ca2+, PTH
6 – 12 m, 
or symptoms
6 – 12 m 12–
24 me
EUS may be required if 
progression is suspected
Other
G1–G2 NETn
resected/
nonresected
yes 3 – 6 m yesd relevant tumor 
hormonesd
12 m, 
or symptoms
6 – 12 m 12–
24 me
EUS may be required if 
recurrence or progression is 
suspected
G3 NEC/NETn resected/
nonresected
yes 3 m yesd none 12 m, 
or symptoms
3 m 12–
24 me,f
12–
24 ml
EUS may be required if 
recurrence or progression is 
suspected
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Table 1 (continued)
Organ Status F-U Every CgA Markersa Endoscopy CT/MRI/USb SRIc FDG-PET Comments
Pancreas
Insulinoma
solitary
G1–G2 NETn
resected yes once
3 – 6 m
yesd fasting BS
insulin
C-peptide
pro-insulin
no no no fasting test performed if 
symptoms recur; EUS may
be required if recurrence is 
suspected
Insulinoma
localized or 
metastases
G1–G2 NETn
nonresected yes 3 – 6 m yesd fasting BS
insulin
C-peptide
pro-insulin
no 3 – 6 m 12 me EBUS may be required if 
progression is suspected
Gastrinoma
G1–G2
resected yes 3 – 6 m yes gastrin, B12, 
Ca2+, PTH
6 – 12 m 12–
24 me
gastric pH measurement or 
secretin test may be 
performed if symptoms 
recur; EUS may be required
if recurrence is suspected
Gastrinoma
G1–G2
nonresected yes 3 – 6 m yes gastrin, B12, 
Ca2+, PTH
3 – 6 m 12–
24 me
EUS may be required if 
progression is suspected
Functional
pNET
G1–G2
localized or 
metastasesn
resected/
nonresected
yes 3 – 6 m yes relevant tumor 
hormonesd
no 3 – 6 m 12–
24 me
EUS may be required if 
recurrence or progression is 
suspected
Nonfunctional 
pNET
G1–G2n
resected/
nonresected
yes 3 – 6 m yes none no 3 – 6 m 12–
24 me
EBUS may be required if 
recurrence or progression is 
suspected
pNET
G3 NEC/
NETn
resected/
nonresected
yes 3 m yesd if functioning 
relevant tumor 
hormonesi
no 2 – 3 m 12–
24 me,f
12–
24 ml
EBUS may be required if 
recurrence or progression is 
suspected
Small intestine
G1–G2 curatively resected yes 6 – 12 m yes 5-HIAA no 6 – 12 m 24 me
G1–G2 residual tumor or 
metastases
yes 3 – 6 m yes 5-HIAA no 3 – 6 m 12 me in patients with carcinoid 
syndrome: NT-pro-BNP and 
echocardiography at least 
yearly
G3 NEC/
NET
resected/
nonresected
yes 3 m yesd relevant tumor 
hormonesi
no 2 – 3 m 12–
24 me,f
12–
24 ml
in patients with carcinoid 
syndrome: NT-pro-BNP and 
echocardiography at least 
yearly
Appendix
G1–G2
<2 cmj
curatively resected no no no no no no no appendectomy
G1–G2
>2 cmk
curatively resected/
nonresected
yes 3 – 6 m yes 5-HIAAd no 3 – 12 m 24 me right hemicolectomy
G3 NEC/
NET
resected/
nonresected
yes 3 m yesd relevant tumor 
hormonesi
no 2 – 3 m 12–
24 me,f
12–
24 ml
in patients with carcinoid 
syndrome: NT-pro-BNP and 
echocardiography at least 
yearly
Colon
G1–G2 curatively resected yes 6 – 12 m yesd 5-HIAAd yes
12 – 24 m
6 – 12 m 24 me serotonin-producing tumors 
of the cecum or if 5-HIAA is 
elevated at diagnosis
G1–G2 residual tumor or 
metastases
yes 3 – 6 m yesd 5-HIAAd yes, if symptoms 3 – 6 m 12 me serotonin-producing tumors 
of the cecum or if 5-HIAA is 
elevated at diagnosis
G3 NEC/
NET
resected/
nonresected
yes 3 m yesd none yes, if symptoms 2 – 3 m 12–
24 me,f
12–
24 ml
Rectum
G1–G2
<1 cm
curatively resected yes once no none once and if 
symptoms
no no EUS may be required if 
recurrence is suspected
G1–G2
1 – 2 cm
curatively/
noncuratively 
resected
yes 12 m yesd none 12 m or if 
symptoms
3 – 12 m 12–
24 me
EUS may be required if 
recurrence or progression is 
suspected
G1–G2
>2 cm
curatively/
noncuratively 
resected
yes 3–
12 m
yesd none 6 – 12 m or if 
symptoms
3 – 12 m 12–
24 me
EUS may be required if 
recurrence or progression is 
suspected
G3
NEC/NET
curatively/
noncuratively 
resected
yes 3 m yesd none 6 – 12 m or if 
symptoms
3 m 12 me,f 12–
24 ml
EUS may be required if 
recurrence or progression is 
suspected
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intervals, are too comprehensive to be included in  Ta-
ble 1 , but are mentioned in  Table 2 .
 Functioning tumors (the specific secreted hormone be-
ing their tumor marker) should be followed up with hor-
mone analyses and imaging every 3–12 months depend-
ing on hormone-related symptoms and tumor aggressive-
ness. If recurrence or persistence is highly suspected, 
functional tests, for example fasting test for insulinomas 
and secretin test for gastrinomas, may be required. 
 Recommendations for Follow-Up Investigations 
 It is recommended that follow-up should be performed 
in specialized NEN centers to obtain specific biochemis-
try and high-quality imaging. 
 General Recommendations 
 Documentation of each patient should encompass:
 • Patient identification and basic demographic details 
 • General health score (Karnofsky status/WHO score/
ECOG performance status) 
 • Patient’s history: onset, extent, and severity of tumor-
specific symptoms, hormone-related syndromes, fam-
ily history, inherited syndromes, metachronous or 
synchronous malignancies 
 • Comorbidity including concomitant diseases, includ-
ing kidney and liver disease 
 • Plasma CgA and relevant hormone levels with refer-
ence to previous levels considering the current unspe-
cific medical treatment of the patient (e.g., proton 
pump inhibitors may induce elevation of plasma CgA 
and gastrin levels) 
 • Presence of carcinoid heart disease 
 • Availability of tumor and/or patient samples, includ-
ing characteristics of the samples and location 
 • Pathological diagnosis including TNM stage (ENETS 
and UICC) and WHO grade (mitotic count or pre-
ferred Ki-67 proliferation index) from resected tumor 
specimens or from biopsies from targeted organs 
 • Development of tumor and metastases and changes in 
tumor burden based on computerized tomography/
magnetic resonance imaging (CT/MRI) and soma-
tostatin receptor imaging (SRI); for SRI, up-take grade 
should be recorded 
 • Preceding and actual treatment(s) 
 • Consider referral to curative or debulking surgery 
 • Consider referral to medical treatment 
 • Consider referral to peptide receptor radionuclide 
treatment  
 • Consider referral to liver-directed interventional treat-
ment  
 • Consider referral to palliative unit for supportive care 
 If relevant from the above, the patient documentation 
should be presented at the multidisciplinary tumor board 
for further planning.
Table 1 (continued)
Organ Status F-U Every CgA Markersa Endoscopy CT/MRI/USb SRIc FDG-PET Comments
Cancer – unknown primary
G1–G2 noncuratively 
resected
yes 3 – 6 m yesd 5-HIAAd no 3 – 6 m 12 me
G3 NEC/
NET
noncuratively 
resected
yes 3 m yesd 5-HIAAd no 3 m 12 me,f 12–
24 ml
 LNEC, large-cell neuroendocrine carcinomas; NET, neuroendocrine tumor; NEC, neuroendocrine carcinoma; pNET, pancreatic neuroendocrine tumor; F-U, follow-up; m, months; 
NSE, neuron-specific enolase; PTH, parathyroid hormone; BS, blood sugar; y, years; EBUS, endobronchial ultrasound; EUS, endoscopic ultrasound.
a Other tumor markers and hormones in blood and urine. b CT is preferred for routine control. c Somatostatin receptor imaging (68Ga-DOTA PET; octreotide scintigraphy). d Only 
if elevated at diagnosis. e Only if positive at diagnosis. f In G3 NEC or atypical pulmonary NET, 18FDG-PET may be used instead. g Are usually elevated, but have no implement on F-U. 
h Only if metastasized; for CT/MRI/US every 6 months, for SRI every 12 – 24 months. i Rarely functioning. j No metastases, no angioinvasion, mesoappendiceal invasion <3 mm. k Or 
metastases, angioinvasion, mesoappendiceal invasion >3 mm, localized at the base, uncertain resection margins. l FDG-PET-CT may be used instead of SRI if positive at diagnosis.
m Only if tumor is visible by bronchoscopy at diagnosis. n Hereditary diseases (MEN-1, VHL and neurofibromatosis type 1 is included).
 Table 2. Shorter intervals between follow-ups in patients with 
NEN
High-grade tumors
Large tumor burden (e.g., liver burden >30% and lung/
bone metastases)
Extensive disease
Aggressive behavior (progression within few months)
Severe (uncontrolled) endocrine symptoms
Weight loss and clinical aggravation
High chromogranin A levels >10 UNL
UNL, upper normal level.
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 General Comments 
 Tumor-specific follow-up investigations are mainly 
based on clinical symptoms, imaging procedures such as 
functional and cross-sectional imaging, and tumor mark-
ers. However, an expert physician who is in charge of an 
individual patient is able to judge the patient’s general 
health and even prognosis by a careful history and exam-
ination, assessment of weight loss, muscular mass and 
symptoms, for example heart function in cases of the car-
cinoid syndrome and possible carcinoid cardiac disease. 
However, these items are difficult to compare inter- and 
intraindividually and should be supported where possible 
by “objective” procedures such as imaging methods and 
serum/plasma tumor markers.
 Tumor Markers 
 Chromogranin A 
 At present, the most common and reliable tumor 
marker is plasma CgA for patients with G1 and G2 NEN. 
However, plasma CgA is generally normal in patients 
with nonfunctioning duodenal NEN, appendiceal NEN, 
small rectal NEN and insulinomas and is often normal in 
patients with localized G1 and G2 NEN and in patients 
with G3 NEN (some G3 NET can have increased CgA 
plasma levels). Plasma CgA may reflect tumor mass and 
changes in tumor burden but also secretory activity of the 
tumor  [9–13] . In addition, plasma CgA may be an indica-
tor for prognosis mainly in small intestinal NEN  [9, 11, 
14] . Furthermore, an increase in the CgA level has been 
suggested as the first indicator of recurrence  [15] . How-
ever, fluctuations in plasma CgA are frequently seen and 
in case of more than 25% increase from the previous lev-
el, determination of CgA should be repeated. If still in-
creased, imaging with CT/MRI or SRI is recommended. 
Plasma CgA may also be elevated without the presence of 
NEN, for example due to the use of proton pump inhibi-
tors, chronic atrophic gastritis, or decreased kidney and 
liver function  [16, 17] .
 In some clinical trials with new targeted agents, signifi-
cant reductions in CgA have been associated with better 
outcomes  [14] . However, variations in plasma CgA with-
out changes in imaging or symptoms compared to baseline 
levels should not be considered for treatment modifica-
tion. Since several assay kits exist, but with no internation-
al standard, caution is recommended when comparing 
values from kits of different manufacturers  [10] . Further-
more, each CgA kit has to be evaluated concerning sensi-
tivity and specificity. CgA levels and normal ranges differ 
in the literature and from laboratory to laboratory and 
from assay to assay because they are measured by different 
methods. Therefore, “cutoff levels” recommended for de-
cision-making should be applied with caution, and each 
institution has to define its own “cutoff levels.”
 Chromogranin B 
 Plasma chromogranin B (CgB) may be of value in the 
follow-up of BP and rectal NEN  [18] . However, the avail-
ability for CgB is limited.
 Neuron-Specific Enolase 
 Plasma neuron-specific enolase may act as an addi-
tional marker in patients with G3 NEN  [19] and has been 
shown to be a prognostic marker in GEP NEN  [14, 20] . 
 5-Hydroxyindoleacetic Acid 
 Twenty-four-hour urine 5-hydroxyindoleacetic acid 
(5-HIAA) is an established marker for patients with sero-
tonin-producing small intestinal/appendiceal and BP 
NEN, in particular in the presence of the “carcinoid syn-
drome.” However, the sensitivity is less than that of plas-
ma CgA  [21] . Recently, analyses for serum 5-HIAA have 
been introduced  [22] . Urine 5-HIAA is influenced by a 
number of dietary factors, for example avocado, banana, 
tomato and others, and by drugs such as coumarin, 
paracetamol, phenacetin, aspirin and others.
 Serotonin 
 Measurement of serum serotonin is not recommended 
for follow-up  [23] .
 Gastrointestinal Hormones 
 In patients with functioning pancreaticoduodenal tu-
mors (insulinoma, gastrinoma, glucagonoma, VIPoma, 
somatostatinoma, etc.), the respective hormones are used 
as diagnostic markers. However, the prognostic value of 
change in hormone values is uncertain.
 NT-pro-Brain Natriuretic Peptide 
 Measurement of NT-pro-brain natriuretic peptide 
(NT-pro-BNP) once yearly or at least every 2nd year is 
recommended in the follow-up of patients with carcinoid 
syndrome to reveal development and to control carcinoid 
heart disease  [24] . It is supplemented by echocardiogra-
phy or eventually MRI of the heart  [25–27] .
 Imaging 
 For G1 and G2 neuroendocrine tumors, which are 
generally slow growing, follow-up imaging is usually be-
tween 6 and 12 months but some patients may require 
imaging evaluation earlier. Better determination of the 
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timing of morphological evaluation is required in studies 
either retrospectively or prospectively.
 Cross-Sectional Imaging  
 Current imaging procedures encompass CT, MRI, ab-
dominal ultrasound (US), with or without contrast en-
hancement, and SRI. Primarily CT is used because of its 
standardized imaging planes that facilitate comparison 
between examinations and since the tissue resolution is 
better in cases of extended tumor load. Additionally, MRI 
may be preferable in younger patients having several im-
aging procedures, to reduce radiation dose. In addition, 
MRI is superior to CT to evaluate liver metastases, pan-
creatic and rectal NEN. Abdominal US may, however, be 
used for follow-up if documentation allows one to com-
pare findings obtained during different follow-up visits. 
US is also valuable for the occasional patients in whom 
liver metastases are better visualized by US than by CT 
and for biopsy of new or rapidly growing lesions.
 Thoracoabdominal CT, including three-phase exami-
nation of the liver, is the preferred imaging for follow-up 
as it is widely available and has relatively low cost. How-
ever, in many centers, abdominal MRI is preferred and if 
resection of liver metastases is considered during follow-
up, it is generally recommended to perform MRI to reveal 
small liver metastases not visualized by CT  [28] . 
 Functional Imaging 
 Somatostatin receptor scintigraphy (SRS) with  111 In-
pentetreotide (octreotide scintigraphy), including planar 
imaging and SPECT, has been the mainstay for SRI al-
though most NEN centers currently perform PET-CT 
with  68 Ga-DOTA-conjugated peptide (e.g., TOC/NOC/
TATE) as this PET imaging technique is superior to SRS 
showing higher sensitivity, spatial resolution, identifica-
tion of more lesions, less radiation, and a shorter investi-
gation time  [29–32] and is therefore preferred in follow-
up. Other PET tracers, such as  64 Cu-DOTATATE-
PET-CT  [30, 31] , 18 F-DOPA-PET-CT  [33–35] and  11 C-
5-HTP-PET  [36] as well as GLP-1 receptor imaging with 
 111 In-DTPA-exendin-4 SPECT-CT  [37] , may be used in 
follow-up if positive at baseline and if available at the cen-
ter. Currently, there are only limited data available of 
PET-based imaging for routine follow-up, and its signifi-
cance in this respect is currently not possible to define. 
However, PET may reveal metastases not seen on SRS or 
CT, particularly in bone and lymph nodes  [30, 31, 33–35] . 
Grade uptake at SRI as well as homogeneity of uptake 
should be specified  [38] , also to evaluate the eligibility for 
peptide receptor radionuclide treatment.
 18 FDG-PET-CT has a higher sensitivity than SRS in 
patients with G3 NEN and should instead be utilized for 
follow-up in this group of patients  [39] . Furthermore, 
 18 FDG-PET-CT is frequently positive in G2 NEN with a 
high Ki-67 index and in aggressive and rapidly growing 
NEN  [39, 40] . In addition,  18 FDG-PET is an important 
prognostic factor in NEN, as patients with a positive PET 
have a significantly poorer prognosis than patients with a 
negative one  [39, 41] . Additionally, evidence of different 
uptake in  18 FDG-PET and SRI in the same patient reflects 
the tumor heterogeneity and could have an impact in de-
cision-making criteria  [42] . However,  18 FDG-PET-CT is 
not commonly used for follow-up and in general only 
when SRI is negative, in patients with G3 NEN or in oth-
er selected subgroups of patients. 
 Endoscopy 
 Upper endoscopy should be utilized in the follow-up 
and control of gastric NEN and colonoscopy and sig-
moidoscopy should be used for the follow-up of patients 
with colorectal NEN. National follow-up strategies should 
be followed to early diagnose metachronously appearing 
secondary gastrointestinal malignancy. Follow-up bron-
choscopy for recurrence is indicated in patients with BP 
neuroendocrine tumors localized preoperatively by bron-
choscopy.
 Endoscopic ultrasonography, eventually with biopsy, 
of the stomach, duodenum, pancreas, and rectum could 
be useful for follow-up in selected patients (T and N stag-
ing) and also in patients with MEN-1. Capsule endoscopy 
(jejunum/ileum) is rarely indicated in the follow-up. En-
doscopic bronchial ultrasonography may be indicated in 
follow-up if biopsy of pathologic peribronchial lymph 
nodes is required.
 Histopathology 
 In patients with tumor or metastatic recurrence and/
or rapid or unexpected progression imaging-guided bi-
opsy should be considered to re-evaluate the Ki-67 pro-
liferation index. An increase may change the treatment 
strategy or may rule out secondary malignances. Biopsies 
should be taken from new or rapidly growing metastases.
 Echocardiography 
 “Carcinoid heart disease” with involvement of the tri-
cuspid and pulmonary valves is observed in up to 10–20% 
of patients with the carcinoid syndrome  [43] . In all pa-
tients with carcinoid syndrome and in patients with G1/
G2 GEP NEN or BP NEN with high 24-h urine, 5-HIAA 
level echocardiography should be performed at diagnosis 
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and thereafter annually or shorter if clinically indicated 
 [25–27] . The measurement of NT-pro-BNP should be 
performed as well  [24] . 
 Progression Rate 
 Progression disease rates within G1/G2 GEP NEN and 
BP NEN are not always well defined only using the grad-
ing system. Stable and slowly growing tumors should be 
differentiated from more aggressive tumors in follow-up 
schedules, i.e., patients with aggressive and rapidly grow-
ing tumors should have a follow-up with imaging every 3 
months while patients with stable or slowly growing tu-
mors may have imaging every 6–12 months ( Tables 1 ,  2 ). 
Efforts to quantify the rate of progression should be per-
formed. Furthermore, if stable disease is seen over longer 
time, the interval between follow-up visits and imaging 
may be further extended. Trying to define the progression 
rate and the influence in follow-up for metastatic disease, 
a proposed timeline for follow-up regarding tumor pro-
gression is given in  Figure 1 .
 Hereditary Diseases 
 Patients with hereditary diseases such as multiple en-
docrine neoplasia type 1 (MEN-1), von Hippel-Lindaus 
syndrome (VHL), or neurofibromatosis type 1 should be 
followed according to the organ of the primary tumor, for 
example the pancreas and duodenum. Guidelines for the 
follow-up of non-GEP disease or manifestations, for ex-
ample parathyroid or pituitary adenomas in MEN-1, 
brain and kidney manifestations in VHL and GIST in 
neurofibromatosis type 1, are not described in these rec-
ommendations as they are beyond the scope of this review 
and are dealt with in several other guidelines. 
 Tumor-Specific Recommendations 
 The recommended follow-up for NEN, including GEP 
NEN, BP (typical and atypical) carcinoids, large-cell neu-
roendocrine carcinomas as well as thymic NEN, is given 
in  Table 1 . The panel agrees that the level of evidence for 
follow-up recommendations is low. The recommenda-
tions are in accordance with those given in the WHO 
2010 classification of GEP NEN, the ENETS 2016 guide-
lines for GEP NEN  [3] and the recent guidelines for BP 
NEN  [7] .
 Follow-up is life-long for most patients, with the ex-
ceptions mentioned in  Table 1 . The comprehensive  Ta-
ble 1 on follow-up is based on the organ of the primary 
tumor and is intended to give a simple overview or cata-
log for the clinician. Therefore, some of the schemes are 
repeated from one organ to the other. The panel did not 
distinguish in the follow-up between patients with G1 
and G2 GEP NEN, whereas patients with G3 GEP NEN 
were considered as a separate group. 
 In general, follow-up for resected or nonresected tu-
mors are placed in the same group, but the intervals be-
tween follow-ups are in general shorter in patients with 
Beginning of 
follow-up
3 months 6 months 9 months 12 months 15 months 18 months 21 months
24 months and
thereaŌer 
Imaging and
biomarkers
Imaging and
biomarkers
Imaging and
biomarkers
Imaging and
biomarkers
Biomarkers Biomarkers
Imaging and
biomarkers
Imaging and
biomarkers
 Fig. 1. Proposed timeline schedule for the follow-up of patients with G1/G2 gastroenteropancreatic neuroendo-
crine neoplasms and bronchopulmonary (typical and atypical) carcinoids regarding tumor progression rate. Ini-
tial follow-up every 3 months with clinical assessment, imaging and biomarkers is suggested to define progression 
rate. If stable disease has been confirmed after 15 months, imaging control could be performed every 6–12 months 
and clinical and biomarker evaluation every 3–6 months. 
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residual tumor or metastases compared to patients with 
curatively resected tumor or metastases as well as in pa-
tients with aggressive disease ( Table 2 ). 
 The follow-up investigations that should be docu-
mented to visualize the specific course of the disease in an 
individual patient are summarized in  Tables 1 and  2 and 
in  Figure 1 . 
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